DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap)
IB 2020-05
Phase 2 small_molecule active
Quick answer
DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion, Bintrafusp alfa (anti-PD-L1/TGFβ Trap) for Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas. is a Phase 2 program (small_molecule) at Institut für biomedizinische Analytik NMR-Imaging GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Institut für biomedizinische Analytik NMR-Imaging GmbH
- Indication
- Adult patients with locally advanced/unresectable and/or metastatic soft-tissue sarcomas.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active